Invizius develops treatments targeting excessive complement system activation, including H-Guard for acute kidney injury in dialysis patients and INV-201 to prevent peritoneal fibrosis.
Streptococcus pneumoniae is a highly invasive bacterial pathogen causing severe diseases like pneumonia, sepsis, and meningitis by surviving in the bloodstream.
Mercia Ventures led a £950,000 funding round for Invizius, supporting the development of its H-Guard treatment for dialysis-related inflammatory responses ahead of clinical trials.
Researchers at the University of Edinburgh discovered how a pathogenic bacterium evades the human immune system, which could help regulate the Complement System for treating diseases driven by its overactivation.
Invizius is developing products to help patients on dialysis, cardiopulmonary bypass, ECMO and on other extra-corporeal treatments, to feel better, and suffer fewer complications.
